• Oncternal Announces First Patient Dosed in Cirmtuzumab, Paclitaxel Trial americanpharmaceuticalreview
    September 13, 2018
    Oncternal Therapeutics announced the first patient has been dosed in a Phase 1b study of cirmtuzumab, an anti-ROR1 monoclonal, in combination with standard-of-care chemotherapy drug paclitaxel in patients with HER2/neu negative metastatic or locally advan
PharmaSources Customer Service